Find disease awareness content and relevant supporting materials
NMPA(China) approves Tuoyi + chemotherapy to treat NSCLC without EGFR mutations or ALK fusions
The China National Medical Products Administration has approved the supplemental new drug application seeking the approval of toripalimab (Tuoyi) plus pemetrexed and platinum as a frontline treatment in patients with unresectable, locally advanced or metastatic, nonsquamous non–small cell lung cancer (NSCLC) who do not harbor EGFR mutations or ALK fusions
Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC)
To evaluate and compare objective response rates in both arms while defining toxicity profiles of both application schedules. Additionally, evaluation of...
A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801)
Patients with inoperable Non-Small-Cell Lung Cancer will receive thoracic radiation therapy 66 Gy over 33 fractions,and concurrent with 2 cycles...